What should you know when entering Pharmaceutical market in Japan?
Various EU products and services began to enjoy benefits from the EU-Japan Economic Partnership Agreement (EPA) which entered in force on 1 February 2019, and we are seeing a considerable increase of EU exports to Japan. But yet many EU exporters, particularly small and medium-scaled enterprises (SMEs) perceive access to Japanese market difficult because of unfamiliar trade and business practices.
This is a series of online training which present the latest market information available in 2020 and explain in practical terms the most important things that EU companies should know when exporting to Japan so that the benefits of free trade can become more widely available to EU exporters for the second year of the EU-Japan EPA.
Japan's pharmaceutical market is particularly attractive for EU companies as it is largely supplied with foreign products and regulatory environments are being improved under the EU-Japan Economic Partnership Agreement (EPA).
This session reviews the latest market trends, healthcare policy and entry requirements so that the benefits of free trade can become more widely available to EU manufacturers exporters for the second and third years of the EU-Japan EPA. The training targets EU companies in the pharmaceutical sector where industrial cooperation, specialization and supply-chain integration are actively promoted between the EU and Japan.
- Expert’s presentation
- Q&A Session
Registration deadline: 3 November 2020
Speaker: Chieko Nakabayashi
Moderator: Pauline Laloux, Business Support Coordinator, EU-Japan Centre
Organiser: EU-Japan Centre for Industrial Cooperation - Brussels Office
Source and more info: https://www.eubusinessinjapan.eu/library/event/export-to-japan-7-technical-regulations---pharmaceuticals